Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Prothena Corporation plc Ordinary Shares

Prothena Biosciences specializes in developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, focusing on the biology of misfolded proteins.

COM:PROTHENA

Prothena Biosciences

Last Close

14.44

22/11 21:00

Market Cap

818.97M

Beta: -

Volume Today

468.84K

Avg: -